Journal
CLINICAL NUCLEAR MEDICINE
Volume 48, Issue 2, Pages E95-E98Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004497
Keywords
ACC; CT; MRI; PET/CT; DOTAGA-IAC; alpha(v)beta(3) integrin
Ask authors/readers for more resources
Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. In this study, Ga-68-DOTAGA-IAC PET/CT imaging was used to noninvasively examine ACC patients, showing promising results for metastatic and recurrent cases. This technique could potentially serve as a valuable radiotracer for ACC.
Adrenocortical carcinoma (ACC) is a rare malignancy with a prevalence of 1 to 2 cases/million/year. The diagnosis depends upon endocrine workup followed by imaging with CT, MRI, and F-18-FDG PET/CT. The treatment includes surgical resection, debulking surgery, chemotherapy, and radiotherapy. However, patients do not respond well to any of the available therapies. We present noninvasive imaging of histopathology-proven ACC patients using Ga-68-DOTAGA-IAC PET/CT, specific for integrin alpha(v)beta(3). Ga-68-DOTAGA-IAC PET/CT 45 minutes after IV injection showed a decent tumor-to-background ratio and could be used as a promising radiotracer for metastatic and recurrent ACC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available